A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).

The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

Event-Free Survival

Objective Response, Freedom from surgery, Pathological Complete Response, Major Pathological Response, Disease-Free Survival, Disease-Specific Survival, Overall Survival, Percentage of Participants Experiencing Adverse Events (AEs), Percentage of Participants Discontinuing Study Treatment Due to AEs, Change in score from baseline evaluated by: - Global Health Status/Quality of Life (QoL) score (QLQ-C30 Items 29 and 30), Change in score from baseline evaluated by: - Physical functioning score (QLQ-C30 Items 1 to 5), Change in score from baseline evaluated by: - Role functioning score (QLQ-C30 Items 6 and 7)

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Belgium, Czechia, France, Germany, Hungary, Italy, Norway, Poland, Romania, Spain